美迪西(688202) - 2025 Q4 - 年度业绩
MedicilonMedicilon(SH:688202)2026-02-27 09:00

Financial Performance - The company achieved total operating revenue of 1,161.14 million yuan, representing a year-on-year growth of 11.89%[3] - The net profit attributable to the parent company was -155.02 million yuan, a reduction in loss of 175.83 million yuan compared to the previous year[5] - The gross profit margin improved by approximately 11 percentage points year-on-year due to cost control and efficiency enhancement measures[6] - The basic earnings per share improved to -1.17 yuan, compared to -2.47 yuan in the previous year[3] - The weighted average return on net assets increased by 6.62 percentage points to -7.62%[3] Business Growth - The company signed new orders worth approximately 1.6 billion yuan, an increase of about 45% year-on-year[7] - The company’s international business revenue increased to approximately 47% of total revenue, reflecting a strategic focus on global expansion[6] Asset Management - Total assets at the end of the reporting period were 2,588.90 million yuan, a decrease of 8.30% from the beginning of the period[4] - The equity attributable to the parent company was 1,947.03 million yuan, down 9.02% from the beginning of the period[4] Market Challenges - The company continues to face pressure on profit margins due to competitive pricing in the market[7]

Medicilon-美迪西(688202) - 2025 Q4 - 年度业绩 - Reportify